Aspire Biopharma Holdings, Inc. filings document the company’s public-company reporting, securities offerings, shareholder votes, governance matters and capital structure. Proxy materials cover stockholder approval matters involving warrant issuances, warrant adjustments, Nasdaq Rule 5635(d) compliance and reverse stock split authority.
Material-event reports and amendments describe securities purchase agreements, Series A convertible preferred stock, registration rights, financing tranches and corrections to prior disclosures. Registration statement filings provide offering disclosures, risk factors, operating and financial information, and security-structure details for the company’s common stock and related securities.
ASBP disclosed that its Audit Committee dismissed Turner Stone & Company, LLP as independent registered public accounting firm effective September 24, 2026, and approved CBIZ CPAs P.C. as the new independent auditor for the fiscal year ending December 31, 2026, effective immediately.
Turner’s report on the financial statements as of December 31, 2025 did not contain an adverse or disclaimer opinion and was not qualified or modified, except for an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern. Management concluded that disclosure controls and procedures were ineffective as of December 31, 2025 due to material weaknesses in internal control over financial reporting. The company reported no disagreements with Turner during 2025 or the subsequent interim periods through September 24, 2026.
Aspire Biopharma Holdings, Inc. (ASBP), now renamed Aspire-Lakewood Holdings, Inc., amended its Delaware charter to effect a corporate name change effective September 8, 2026; the Nasdaq listing, ticker and CUSIP remain the same and stockholders do not need to take any action.
The company’s board also authorized a $10 million common stock repurchase program effective September 9, 2026. Aspire-Lakewood highlights its newly acquired subsidiary, Dura Control Systems Corp. (DCSC), which generated 2025 revenue of about $209.5 million and Adjusted EBITDA of $22.3 million, and revenue of about $103.9 million and Adjusted EBITDA of $10.5 million for the six months ended June 30, 2026. With roughly 1.5 million common shares outstanding as of September 8, 2026, management views the repurchase authorization as an opportunistic use of capital, while noting repurchases may vary or be suspended based on conditions.
Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) reported that it has changed its corporate name to Aspire-Lakewood Holdings, Inc., effective upon filing a Certificate of Amendment to its Certificate of Incorporation with the Delaware Secretary of State. The company’s common stock will continue to trade on The Nasdaq Capital Market under the same ticker symbol, and existing stock certificates remain valid.
The name change, approved by the board and stockholders under Section 242 of the Delaware General Corporation Law, is positioned as aligning the company’s holding company structure with its expanded focus following the acquisition of Dura Control Systems Corp. (DCSC), a designer and manufacturer of engineered automotive and industrial control systems. The change does not alter stockholder rights or require any action by stockholders.
Aspire Biopharma Holdings, Inc. (ASBP) reported that it plans to distribute an investor presentation on August 19, 2026. The company furnished this presentation as Exhibit 99.1 to provide additional information to the market under a Regulation FD disclosure.
The common stock and public warrants of Aspire Biopharma Holdings, Inc. trade on The Nasdaq Stock Market LLC under the symbols ASBP and ASBPW, respectively. The report was authorized on behalf of the company by Chief Executive Officer Kraig Higginson.
Highbridge Capital Management, LLC filed Amendment No. 1 reporting beneficial ownership of Aspire Biopharma Holdings, Inc. common stock issuable upon exercise of warrants held by its advised funds. Highbridge reports 78 shares of common stock with sole voting and dispositive power, representing 0.0% of the class based on 1,295,234 shares outstanding as of May 13, 2026. The position is held on behalf of certain Highbridge funds, and overall ownership is disclosed as 5 percent or less of the class.
Aspire Biopharma Holdings, Inc. reported minimal commercial activity but a much stronger balance sheet for the quarter and six months ended June 30, 2026. Net revenue was $63,104 for the quarter and $91,457 for the first half of 2026, producing a negative gross margin due to $73,421 of cost of revenue and a $42,372 inventory write-off. The company remains in an early commercialization phase.
The operating loss was $2.68 million for the quarter and $4.32 million year-to-date, but total net loss of $4.49 million for the first half of 2026 improved significantly from $17.92 million a year earlier as prior-period stock-based compensation and financing-related charges rolled off. Cash and cash equivalents increased to $12.17 million from $1.00 million at December 31, 2025, and working capital reached $11.78 million.
Major capital structure changes included issuance of 26,250 shares of Series A Convertible Preferred Stock in February and April 2026, of which 17,050 remained outstanding at June 30, 2026, and multiple conversions of debt and preferred stock into common shares, increasing common shares outstanding to 1,295,234 after two reverse stock splits. Total liabilities fell to $1.78 million from $7.69 million, turning a $(6.38) million stockholders’ deficit into positive equity of $11.76 million. Management states existing liquidity is sufficient to fund operations for at least one year after issuance of these statements.
Aspire Biopharma Holdings, Inc. shareholder Gary Shirinyan reported his ownership of the company’s common stock. He beneficially owns 99,900 shares of common stock, representing 7.7% of the outstanding class. He has sole voting power and sole dispositive power over all 99,900 shares, with no shared voting or dispositive authority.
Aspire Biopharma Holdings, Inc. completed the acquisition of Dura Driver Control Systems (DCS), purchasing 100% of DCS’s shares for approximately $30.0 million in cash. DCS, a tier-one automotive systems supplier, becomes a wholly owned subsidiary and is expected to enhance Aspire’s revenue, earnings and cash flow profile.
DCS generated unaudited revenue of $209.5 million and Adjusted EBITDA of $22.3 million in 2025, and revenue of $103.9 million and Adjusted EBITDA of $10.5 million for the six months ended June 30, 2026. Aspire entered into a $22.5 million senior secured revolving credit facility to help fund the acquisition alongside cash on hand.
The board also approved and the company issued convertible promissory notes with an aggregate principal of $3,750,000, sold for $3,000,000 (a 20% original issue discount), intended for working capital and future growth opportunities. These notes are convertible into common stock at a $8.00 per-share conversion price and were issued in a private offering relying on Section 4(a)(2) and Rule 506(b) exemptions.
Lance Friedman reports beneficial ownership of common stock of Aspire Biopharma Holdings, Inc. on an amended Schedule 13G. He is a United States citizen and lists 25 N Market Street, Suite 205, Jacksonville, Florida as his address. Friedman reports beneficial ownership of 107,323 shares of common stock, representing 7.92% of the class, with sole voting and sole dispositive power over all 107,323 shares and no shared power. The holdings include 107,323 shares of common stock with a floor price of $7.92 per share. He also holds preferred stock that is convertible into common stock but subject to a 9.99% ownership blocker, which prohibits conversion if it would cause his ownership to exceed 9.99% of Aspire Biopharma’s outstanding common stock.
Aspire Biopharma Holdings, Inc. clarified the current terms of its Nasdaq-listed public warrants, which trade under the symbol ASBPW, following requests from warrant holders. The warrants were originally issued on February 23, 2022 in connection with the initial public offering of its predecessor, Power Up Acquisition Corp.
The warrants initially had an exercise price of $11.50 per share, subject to adjustment for events such as share consolidations. After a 1-for-30 reverse stock split on January 16, 2026 and an additional 40-for-1 reverse split on May 11, 2026, each public warrant now carries an exercise price of $13,800 per share and a ratio of 1,200 warrants to purchase one share of common stock.